Article Text

other Versions

PDF
Paper
Why cure, why now?
  1. Daniel R Kuritzkes1,2
  1. 1Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA
  2. 2Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Dr Daniel R Kuritzkes, Division of Infectious Diseases, Brigham and Women's Hospital, Boston MA, 02139 USA; dkuritzkes{at}partners.org

Abstract

Combination antiretroviral therapy (cART) is highly effective at preventing morbidity and mortality due to infection with human immunodeficiency virus (HIV), but does not eradicate the virus. Consequently, cART must be administered life-long. Recent progress has stimulated research towards a cure of HIV infection. Approaches under investigation include hematopoietic stem cell transplantation, latency reactivating agents, immune based therapies, and cell-based therapies. Each of these approaches carries potential risks that must be weighed against the availability of safe and effective cART. Balancing the risks and benefits of this research poses unique challenges to potential study participants, clinicians and investigators.

  • HIV Infection and AIDS
  • Clinical trials
  • Ethics

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.